EXPRS2.ST
ExpreS2ion Biotech Holding AB (publ) [EXPRS2.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
EXPRS2.ST Stock Summary
In the News
EXPRS2.ST Financial details
Company Rating
-
Market Cap
112.58M
Income
-95.99M
Revenue
5.94M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
08 Feb 2024
P/E
-1.45
Forward P/E
-
PEG
0.45
P/S
27.7
P/B
2.29
P/C
-
P/FCF
-1.5
Quick Ratio
4.04
Current Ratio
5
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.12
EPS next Y
-
EPS next Q
-
EPS this Y
-33.76%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
15.09%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-20.45%
-
-
-
-
SMA20
-1.87%
SMA50
-18.93%
SMA100
-35.67%
Inst Own
-
Inst Trans
-
ROA
-124%
ROE
-139%
ROC
-1.67%
Gross Margin
36%
Oper. Margin
-2003%
Profit Margin
-1833%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.713-6.46
52W High
-
52W Low
-
RSI
52.86
Rel Volume
0.09
Avg Volume
126.68K
Volume
11.64K
Perf Week
10.67%
Perf Month
-8.4%
Perf Quarter
-40.11%
Perf Half Y
-34.38%
-
-
-
-
Beta
1.762
-
-
Volatility
0.46%, 0.94%
Prev Close
5.66%
Price
16.8
Change
8.25%
Company Profile
- Volume Average 126.68K
- Market Capitalization 112.58M
- Employee 20
- CEO Mr. Bent U. Frandsen MSc
- Headquarters Horsholm,DK
- IPO Date 2016-07-29
-
Website
https://www.expres2ionbio.com 
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.
